FindTrial
Sign In

New Application of an "Old" Marker for Predicting the Prognosis of Patients with Pancreatic Cancer-Serum CK-MB-to-Total-CK Ratio

New Application of an "Old" Marker for Predicting the Prognosis of Patients with Pancreatic Cancer-Serum CK-MB-to-Total-CK Ratio

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071736
Enrollment
Unknown
Registered
2023-05-24
Start date
2023-05-24
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

High CK ratio group:NA
Low CK ratio group:NA

Sponsors

Department of General Surgery, Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
26 Years to 82 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with pancreatic adenocarcinoma by biopsy of the resection specimen or laparoscopic-assisted puncture biopsy at Fujian Medical University Union Hospital from June 2016 to December 2021.

Exclusion criteria

Exclusion criteria: 1. Malignancy history; 2. Missing information on TNM stage or CA19-9 value; 3. Stroke history; 4. Myocardial infarction history; 5. Progressive muscular dystrophy, polymyositis or dermatomyositis.

Design outcomes

Primary

MeasureTime frame
CK ratio;Overall survival;—

Secondary

MeasureTime frame
Height;Blood routine;Weight;Blood Glucose;Albumin;Tumor stage;Surgery;Chemotherapy;Sex;Age;Vascular invasion;Tumor differentiation;Lymphatic invasion;Resection margin;Perineural invasion;—

Countries

China

Contacts

Public ContactFengchun Lu

Department of General Surgery, Fujian Medical University Union Hospital

fengchun160lu@fjmu.edu.cn+86 199 0500 5634

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026